Patient-Reported Outcomes and Considerations in the Management of COPD: Focus on Aclidinium

Total Page:16

File Type:pdf, Size:1020Kb

Patient-Reported Outcomes and Considerations in the Management of COPD: Focus on Aclidinium Journal name: Patient Preference and Adherence Article Designation: Review Year: 2015 Volume: 9 Patient Preference and Adherence Dovepress Running head verso: Lopez-Campos et al Running head recto: Aclidinium and patient-reported outcomes open access to scientific and medical research DOI: http://dx.doi.org/10.2147/PPA.S55009 Open Access Full Text Article REVIEW Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium Jose Luis Lopez-Campos1,2 Abstract: Chronic obstructive pulmonary disease (COPD) is a complex heterogeneous disease, Carmen Calero1,2 in which several factors combine to give the final clinical expression. Both early and more 1 recent studies have shown that forced expiratory volume in one second (FEV ), despite being Cecilia Lopez-Ramirez 1 Maria Isabel Asensio-Cruz1 an extremely important parameter to predict the progression of the disease, is a poor surrogate Eduardo Márquez-Martín1 marker for symptoms perception. Accordingly, patient-reported outcomes (PROs) have gained Francisco Ortega-Ruiz1,2 popularity as a measure of the impact of treatment from the patients’ perspective, since they represent the individuals’ perception of their health status, beyond any physiological limitations. 1 Unidad Médico-Quirúrgica de Several such PROs, therefore, are currently included in multidimensional COPD evaluation. Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla This multidimensional approach helps identify different patient types and individualize, up to (IBiS), Hospital Universitario Virgen a certain point, pharmacological treatment. In this multidimensional approach it is important to del Rocío/Universidad de Sevilla, highlight the importance of long-acting bronchodilators in COPD treatment strategies. Long- Sevilla, 2CIBER de Enfermedades Respiratorias (CIBERES), Instituto de acting bronchodilators are cost-effective and have been shown to achieve the greatest functional Salud Carlos III, Madrid, Spain and clinical improvements in COPD. As a result, long-acting bronchodilators are now the main pharmacological treatment for COPD at all stages of the disease. Until recently, tiotropium was the leading bronchodilator for the treatment of COPD. The clinical development of this medi- cation, unprecedented in inhaled therapy, involved tens of thousands of patients and yielded consistent outcomes in terms of lung function, symptoms, quality of life, exacerbations, and prognosis. However, new long-acting bronchodilators have recently been developed or are cur- rently under development. In this review, we evaluate the effects of aclidinium bromide, a novel long-acting bronchodilator, on PROs in COPD. Aclidinium is a novel long-acting muscarinic antagonist with a good safety profile for the treatment of COPD, and has proven efficacy in both objective functional measurements and PROs. Comparison studies with tiotropium have shown it to have similar lung function improvement and a similar impact on PROs, including quality of life or symptom perception. Keywords: patient-reported outcomes, chronic obstructive pulmonary disease, bronchodila- tors, aclidinium Introduction Although recent studies have shown a steady decrease in chronic obstructive pulmonary disease (COPD) mortality,1 it is still the third leading cause of death.2 Additionally, the impact of COPD on health-related quality of life3 and the burden on health care systems4 make it a disease of the first order. Correspondence: Jose Luis Lopez- Campos As an obstructive disease, the main parameter to evaluate progression is the degree Unidad Médico-Quirúrgica de of airflow obstruction measured by the forced expiratory volume in one second (FEV1) Enfermedades Respiratorias, Instituto obtained during a forced spirometry. As a result, traditional clinical trials have focused de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/ on demonstrating improvement in FEV1 either as an isolated measurement or as a Universidad de Sevilla, Avda Manuel declining trend over time.5 Accordingly, previous guidelines focused on establishing Siurot, s/n, 41012 Sevilla, Spain 6 Email [email protected] treatment strategies according to the degree of FEV1 impairment. submit your manuscript | www.dovepress.com Patient Preference and Adherence 2015:9 95–104 95 Dovepress © 2015 Lopez-Campos et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further http://dx.doi.org/10.2147/PPA.S55009 permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Lopez-Campos et al Dovepress However, COPD is a complex heterogeneous disease, Consequently, in recent years, a shift toward patient- in which several factors combine to give the final clinical centered medicine has been proposed, and several initiatives expression. Both early and more recent studies have shown have been put forward to include other clinical variables that, despite being an extremely important parameter to pre- in the so-called multidimensional evaluation of the COPD dict the progression of the disease, FEV1 is a poor surrogate patient, in which FEV1 continues to play a prominent role, marker for symptoms perception. In the Evaluation of COPD but is modulated by other clinical disease expressions.9 Longitudinally to Identify Predictive Surrogate End-points Accordingly, since the 2011 update, the Global initiative (ECLIPSE) study, a large, 3-year observational controlled for chronic Obstructive Lung Disease incorporates a three- multicenter international study aimed at defining clinically pronged approach (lung function, chronic symptoms, and relevant subtypes of COPD,7 the authors very elegantly exacerbations) to identify types of patients who may need 10 11 showed the complex interaction between FEV1 and clinical different treatment strategies. Although controversial, one markers. As a result, although clinical symptoms worsen of the strengths of this approach is the inclusion of patient- as FEV1 decreases in the cohort of patients, when it comes reported outcomes (PROs) as part of the evaluation system. down to the individual patient, the authors found different PROs have gained popularity as a measure of the impact of degrees of impairment in symptoms or exacerbations in treatment from the patients’ perspective, since they represent 8 all FEV1-mediated COPD degrees of severity (Figure 1). the individuals’ experience of their health status, beyond any This suggested that new markers of disease expression and physiological limitations.12,13 This multidimensional approach progression were needed to make a correct and more com- helps identify different patient types and individualize, up to prehensive evaluation of COPD patients. a certain point, pharmacological treatment. (A)(Rho=–0.36 B) Rho=–0.34 P<0.001 P<0.001 1,000 4 800 3 ) 600 2 400 1 6MWD (m mMRC score 200 0 0 0 20 40 60 80 20 40 60 80 Post-dose FEV1 (% predicted) Post-dose FEV1 (% predicted) (C) Rho=–0.21 (D) Rho=–0.38 P<0.001 P<0.001 7 100 e 6 80 5 4 60 3 40 2 1 20 0 SGRQ-C total scor 0 Number of exacerbations 020406080 20 40 60 80 Post-dose FEV1 (% predicted) Post-dose FEV1 (% predicted) Figure 1 Relationship between the severity of airflow limitation and breathlessness as assessed by the mMRC questionnaire (panel A), exercise capacity as assessed by the 6MWD (panel B), reported exacerbations in the year before inclusion in the study (panel C), and health status as assessed by the SGRQ-C (panel D). Notes: Copyright ©2010. Agusti A, Calverley PM, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.8 Abbreviations: mMRC, modified Medical Research Council; SGRQ-C, St George’s Respiratory Questionnaire – COPD specific; 6MWD, 6-minute walking distance. 96 submit your manuscript | www.dovepress.com Patient Preference and Adherence 2015:9 Dovepress Dovepress Aclidinium and patient-reported outcomes In this system, it is important to highlight the impor- colonization, or different tests to identify the Asthma and tance of long-acting bronchodilators in COPD treatment COPD Overlap Syndrome.21,22 However, objective measure- strategies. Long-acting bronchodilators are cost-effective14 ments correlate poorly with the patient’s subjective experi- and have been shown to achieve the greatest functional and ence, and should be complemented by subjective PRO. clinical improvements in COPD.15 As a result, long-acting The term PRO has been coined to describe the patient’s bronchodilators are now the main pharmacological treatment self-perceived health status.13 PROs are outcomes reported for COPD at all stages of the disease.16 directly by patients, usually by means of self-administered Until recently, tiotropium was the leading bronchodilator questionnaires or diaries, or during a structured interview. In for the treatment of COPD. The clinical development of this this way, they capture the individual’s experiences of COPD medication, unprecedented in inhaled therapy, has involved without any interpretation from
Recommended publications
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting
    FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting August 31, 2020 sNDA 209482: fluticasone furoate/umeclidinium/vilanterol fixed dose combination to reduce all-cause mortality in patients with chronic obstructive pulmonary disease NDA209482/S-0008 PADAC Clinical and Statistical Briefing Document Fluticasone furoate/umeclidinium/vilanterol fixed dose combination for all-cause mortality DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the supplemental New Drug Application (sNDA) 209482, for fluticasone furoate/umeclidinium/vilanterol, as an inhaled fixed dose combination, for the reduction in all-cause mortality in patients with COPD, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered
    [Show full text]
  • Long-Acting Beta-Agonists in the Management of Chronic Obstructive Pulmonary Disease: Current and Future Agents
    UCLA UCLA Previously Published Works Title Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Permalink https://escholarship.org/uc/item/7s74p6sc Journal Respiratory Research, 11(1) ISSN 1465-9921 Authors Tashkin, Donald P Fabbri, Leonardo M Publication Date 2010-10-29 DOI http://dx.doi.org/10.1186/1465-9921-11-149 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Tashkin and Fabbri Respiratory Research 2010, 11:149 http://respiratory-research.com/content/11/1/149 REVIEW Open Access Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Donald P Tashkin1*, Leonardo M Fabbri2 Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting b2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limita- tion, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clini- cally meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated. Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Drug Tariff Part VIIIA December 2019
    12/2019 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Part VIIIA - Basic Prices of Drugs Product List Part VIIIA products A Abacavir 600mg / Lamivudine 30 19000 C Lupin Healthcare 300mg tablets (UK) Ltd Abatacept 125mg/1ml solution for 4 120960 C Orencia ClickJect injection pre-filled disposable devices Abatacept 125mg/1ml solution for 4 120960 C Orencia injection pre-filled syringes Acacia spray dried powder 250 g 1632 C J M Loveridge Ltd Acamprosate 333mg gastro- 168 3770 K A resistant tablets Acarbose 100mg tablets 90 2529 A Acarbose 50mg tablets 90 1458 A Acebutolol 100mg capsules 84 1497 C Sectral Acebutolol 200mg capsules 56 1918 C Sectral Acebutolol 400mg tablets 28 1862 C Sectral Aceclofenac 100mg tablets 60 962 A Acenocoumarol 1mg tablets 100 462 C Sinthrome Acetazolamide 250mg modified- 30 1666 C Diamox SR release capsules Acetazolamide 250mg tablets 112 1029 M Acetic acid 2% ear spray S 5ml 410 C EarCalm Acetone liquid 50 ml 112 A Acetylcysteine 200mg oral powder 30 11250 A sachets sugar free Acetylcysteine 2g/10ml solution for 10 2126 C Martindale infusion ampoules Pharmaceuticals Ltd Acetylcysteine 5% eye drops S 10 ml 3346 C Ilube Acetylcysteine 600mg capsules 30 3998 A Acetylcysteine 600mg effervescent 30 550 C tablets sugar free Aciclovir 200mg dispersible tablets 25 147 A Aciclovir 200mg tablets 25 133 M Aciclovir 200mg/5ml oral 125 ml 3578 A suspension sugar free Aciclovir 3% eye ointment S 4.5 g 934 C Zovirax Aciclovir 400mg dispersible tablets 56 1199 A Aciclovir 400mg tablets 56 310 M Aciclovir
    [Show full text]
  • Cdr Clinical Review Report for Incruse Ellipta
    Common Drug Review Clinical Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indicated for long-term, once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive Indication pulmonary disease (COPD), including chronic bronchitis and emphysema. List in a similar manner to other long-acting muscarinic antagonists Listing request (LAMAs) as a maintenance bronchodilator treatment for COPD. Dosage form(s) Dry powder for oral inhalation, 62.5 mcg per inhalation Manufacturer GlaxoSmithKline Canada Inc. (GSK) This review report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). In addition to CADTH staff, the review team included a clinical expert in respirology who provided input on the conduct of the review and the interpretation of findings. Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • (Lamas) a New Frontier for COPD and Asthma Treatment
    White Paper Long-Acting Muscarinic Agents (LAMAs) A New Frontier for COPD and Asthma Treatment LAMAs in Asthma and COPD Table of Contents 1. Introduction ............................................................................................. 3 2. Tiotropium Bromide ................................................................................. 4 3. Tiotropium + Olodaterol .......................................................................... 7 4. Aclidinium Bromide ................................................................................. 8 5. Aclidinium + Formoterol (ACLIFORM) ....................................................... 9 6. Glycopyrronium Bromide ....................................................................... 10 © 7. Glycopyrronium Bromide + Indacaterol (ULTIBRO )............................... 11 8. Glycopyrronium Bromide + Formoterol .................................................. 13 9. Umeclidinium ........................................................................................ 13 10. Umeclidinium + Vilanterol ..................................................................... 14 11. Triple Therapy ........................................................................................ 16 12. Conclusions ............................................................................................ 16 13. About the Author ................................................................................... 17 14. About CROMSOURCE ............................................................................
    [Show full text]
  • Pipelinetr Ends
    June 2011 PIPELINE TRxENDS PIPELINE TR ENDS is produced by the x 1-3 Promising New Agents 5 Industry Trends University of Massachusetts Medical School’s 4 Projected Generic Entry 5 Additional Promising Clinical Pharmacy Services division and 4 Investigational Indications New Agents distributed to our clients twice yearly. 4 FDA Updates In This Issue Promising New Promising New Agents Agents Aflibercept Drug Name: Aclidinium bromide Drug Name: Aflibercept BLA submitted Manufacturer: Almirall, Forest Manufacturer: Regeneron, Bayer for wet age- Phase III Indication: COPD BLA Indication: Wet AMD related macular Formulation: Dry powder inhaler Formulation: Intravitreal injection degeneration Dimethyl fumarate Aclidinium bromide, a long-acting, inhaled Aflibercept is under FDA review for the treatment NDA submission anticholinergic bronchodilator, is an antagonist at of the neovascular form of age-related macular planned for the M2 and M3 muscarinic receptors. It is being degeneration (wet AMD). By inhibiting vascular relapsing-remitting multiple sclerosis studied for the treatment of chronic obstructive endothelial and placental growth factors, aflibercept pulmonary disease (COPD). may reduce the abnormal growth of blood vessels Projected Three Phase III, randomized, double-blind trials that damage the retina through blood and fluid leaks. Generic Entry compared aclidinium bromide 200 μg and 400 μg In two double-blind, non-inferiority, Phase III ® Nasacort AQ twice daily to placebo in patients with moderate to studies, VIEW 1 (N=1,217) and VIEW 2 (N=1,240), Levaquin® severe COPD. In each study, the primary endpoint patients with wet AMD were randomized to Uroxatral® Anzemet® was the change in morning trough forced expiratory intravitreal aflibercept 0.5 mg monthly, 2 mg monthly, Zyprexa® volume in one second (FEV1), from baseline to week or 2 mg every two months following three monthly Zyprexa® Zydis® 12.
    [Show full text]
  • Profile of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease
    International Journal of COPD Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease Michael W Sims Abstract: Bronchodilators provide the mainstay of pharmacologic therapy for chronic Reynold A Panettieri, Jr. obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for Pulmonary, Allergy, and Critical Care Division, Airways Biology Initiative, the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are Department of Medicine, University in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic of Pennsylvania School of Medicine, Philadelphia, PA, USA bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a sufficient duration of action to provide once-daily dosing. This article will provide a pharma- cologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and efficacy in the treatment of COPD. Keywords: aclidinium bromide, bronchodilators, pulmonary disease, chronic obstructive, muscarinic antagonists, pharmacokinetics, pharmacology Introduction Chronic obstructive pulmonary disease (COPD) is characterized, in part, by chronic airflow
    [Show full text]
  • Novel Asthma Therapies: a Review
    30 Current Drug Therapy, 2012, 7, 30-35 Novel Asthma Therapies: A Review Preeti Chopra1, Inderpal Randhawa1,2 and Terry Chin2,* 1Department of Medicine, VA Greater Los Angeles Healthcare System/UCLA, USA; 2Department of Pediatrics, Miller Children’s Hospital, University of California, Irvine, USA Abstract: Objective: To describe novel medical therapies in asthma. Data Sources: A comprehensive Pub Med search was performed and studies published between 2000 and 2008 were reviewed. Updated studies from 2009 to 2011 were also included. A focus was placed on randomized, controlled studies. Results: Indacaterol, a once daily inhaled long acting beta 2-agonist (LABA) increased forced expiratory volume in 1 sec (FEV1) and resulted in prolonged bronchodilation. Ciclesonide, a pro-drug inhaled corticosteroid, has been shown to increase FEV1 as well as improve morning, evening, and site-measured peak expiratory flow (PEF) with fewer adverse effects. Fluticasone/formoterol (Flutiform), a combination inhaled corticosteroid and LABA, showed a reduction in severe exacerbations requiring hospitalization, increased FEV1, less rescue medication use and higher quality of life scores. Extra-fine beclomethasone with formoterol also appears promising. Several immunomodulating drugs are on the horizon. Roflumilast, an oral once-daily PDE-4 inhibitor, improved forced vital capacity (FVC) and reduced the need for rescue medication. There are encouraging results with mepolizumab and reslizumab, anti-leukin-5 monoclonal antibody preparations, in a specific subset of asthmatic patients. Other approaches such as anti-interleukin-5 receptor blockage and anti-interleukin-9 monoclonal antibodies are in the early stages of development. On the other hand, treatment directed toward anti-tumor necrosis factor in asthmatics has been disappointing.
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]